Hepatocellular carcinoma
Conditions
Interventions
Group A:Epirubicin
Group B:Arsenic Trioxide
Group C:Epirubicin + Arsenic Trioxide
Sponsors
The first Hospital Affiliated to China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male and Female patients aged 18 to 75 years old; 2. Histology or cytology confirmed in patients with primary liver cancer; or clinical diagnosis of liver cancer in line with standards (AFP increased a imaging, AFP is not high two kinds of imaging (CT + C, MR + C) check characteristic Performance; 3. At least one measurable lesion (bulky or nodular type); 4. BCLC stage: B to C phase; 5. ECOG score 0-2 points on the General Status; 6. Expected survival >=3 months; 7. liver function: Child A or B; 8. Able to follow-up with good compliance; 9. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Portal hypertension associated with portal vein tumor thrombus, collateral blood vessel formation was less; 2. Severe liver cell jaundice, liver failure or a large number of ascites; 3. Serious heart, kidney dysfunction, or coagulation dysfunction; 4. Liver tumor volume accounting for 70% or more; 5. Uncontrolled infection; 6. Pregnant or lactating patients; 7. Distant metastasis has occurred, lung metastasis; 8. Systemic failure; 9. Enrolled into the group lost to follow within the post-March.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Survival time;Quality of life scor; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to recurrence, TTR;Remission;Time to progression, TTP; | — |
Countries
China
Contacts
Public ContactKe Xu
Outcome results
None listed